drugset / Trial / NCT07482657
A Phase 2 Study to Investigate the Efficacy and Safety of Zelicapavir in Participants Aged ≥28 Days to ≤36 Months of Age Infected With Respiratory Syncytial Virus
Phase 2
Recruiting
150 enrolled
Enanta Pharmaceuticals, Inc
AMS-PHPT Research Collaboration, Chiang Mai University · collabPENTA Foundation · collab
RandomizedParallel-groupTriple-blindTreatment
Summary
Zelicapavir is a novel, orally administered, nonfusion replication inhibitor of RSV. It is being investigated in this Phase 2 study (EDP 938-203) as a potential treatment for RSV infection in both hospitalized and non-hospitalized children aged ≥28 days to ≤36 months who present with symptomatic RSV infection.
Timeline
- Start
- 2026-07-09
- Primary completion
- 2026-12
- Completion
- 2026-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | zelicapavir | Small molecule | — | Oral |